Yinghong Wang

Dr. Wang has a strong academic background (M.D., Ph.D., M.Sc.) and profound clinic experience from world renowned medical programs (Johns Hopkins, Cleveland Clinic). She holds 14 peer-reviewed publications. Dr. Wang speaks English and Mandarin Chinese fluently. Dr. Wang specializes in Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and immunotherapy induced colitis.

Prior to joining The University of Texas MD Anderson Cancer Center, Dr. Wang had 8 years of experience from a tertiary IBD practice at Cleveland Clinic taking care of patients with Crohn’s Disease, and Ulcerative Colitis with or without serious complications. In addition, Dr. Wang had 2 years of clinic experience doing FMT for recurrent C diff infection at Cleveland Clinic with eradication rate of over 95%.

At MD Anderson, Dr. Wang is currently participating a clinical trial with Infectious Disease and Cancer Prevention Group investigating the role of STAT3 in IBD patients who are high risk population for colon cancer. Qualified IBD patients will be screened and offered the opportunity of participating in this trial.

Meanwhile, Dr. Wang is offering the FMT treatment for the same indication at MD Anderson. FMT has become standard of care for recurrent C Diff infection given its high success rate compared to 30-40% from medical treatments based on the current ACG practice guideline. She is also actively involved in multiple research projects in collaboration with Oncology, and Stem Cell Transplant group at MD Anderson to explore the possibility of doing FMT as a novel treatment option for melanoma, immunotherapy-induced colitis, Graft-vs-Host disease for leukemia patients post stem cell transplantation.